2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.
Richard R. Furman, MD, professor of medicine, Morton Coleman, MD Distinguished Professor of Medicine, director, CLL Research Center, Weill Cornell Medicine, attending physician, NewYork-Presbyterian Hospital, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia (CLL).
There are several important prognostic markers in CLL, explains Furman. For example, those that indicate resistance to BTK inhibition, such as cysteine 481, and those that indicate the likelihood of developing Richter’s transformation.
Other markers, include 17p deletion, TP53 dysfunction, complex karyotype, MYC abnormalities, NOTCH1 mutations, and certain stereotyped IGHV genes, such as IGHV 4-39, says Furman.